Neurogene Inc. (NGNE)
Neurogene Statistics
Share Statistics
Neurogene has 14.93M shares outstanding. The number of shares has increased by 15.02% in one year.
| Shares Outstanding | 14.93M |
| Shares Change (YoY) | 15.02% |
| Shares Change (QoQ) | -28.84% |
| Owned by Institutions (%) | 93.57% |
| Shares Floating | 11.74M |
| Failed to Deliver (FTD) Shares | 1.77K |
| FTD / Avg. Volume | 0.63% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is -5.16 and the forward PE ratio is -2.07. Neurogene's PEG ratio is -0.09.
| PE Ratio | -5.16 |
| Forward PE | -2.07 |
| PS Ratio | 418.98 |
| Forward PS | 1.5 |
| PB Ratio | 1.25 |
| P/FCF Ratio | -5.43 |
| PEG Ratio | -0.09 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Neurogene.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.84, with a Debt / Equity ratio of 0.04.
| Current Ratio | 20.84 |
| Quick Ratio | 20.84 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.17 |
| Interest Coverage | -6883.75 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $8.64K |
| Profits Per Employee | $-702.28K |
| Employee Count | 107 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -63.71% in the last 52 weeks. The beta is 1.47, so Neurogene's price volatility has been higher than the market average.
| Beta | 1.47 |
| 52-Week Price Change | -63.71% |
| 50-Day Moving Average | 15.02 |
| 200-Day Moving Average | 29.96 |
| Relative Strength Index (RSI) | 46.39 |
| Average Volume (20 Days) | 282.24K |
Income Statement
In the last 12 months, Neurogene had revenue of 925K and earned -75.14M in profits. Earnings per share was -4.43.
| Revenue | 925K |
| Gross Profit | 925K |
| Operating Income | -82.61M |
| Net Income | -75.14M |
| EBITDA | -71.89M |
| EBIT | -75.13M |
| Earnings Per Share (EPS) | -4.43 |
Balance Sheet
The company has 136.59M in cash and 12.43M in debt, giving a net cash position of 124.16M.
| Cash & Cash Equivalents | 136.59M |
| Total Debt | 12.43M |
| Net Cash | 124.16M |
| Retained Earnings | -262.3M |
| Total Assets | 335.73M |
| Working Capital | 300.77M |
Cash Flow
In the last 12 months, operating cash flow was -70.6M and capital expenditures -808K, giving a free cash flow of -71.41M.
| Operating Cash Flow | -70.6M |
| Capital Expenditures | -808K |
| Free Cash Flow | -71.41M |
| FCF Per Share | -4.21 |
Margins
Gross margin is 100%, with operating and profit margins of -8930.27% and -8123.68%.
| Gross Margin | 100% |
| Operating Margin | -8930.27% |
| Pretax Margin | -8123.68% |
| Profit Margin | -8123.68% |
| EBITDA Margin | -7771.35% |
| EBIT Margin | -8930.27% |
| FCF Margin | -7720.11% |
Dividends & Yields
NGNE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NGNE is $66, which is 475.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $66 |
| Price Target Difference | 475.9% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Dec 19, 2023. It was a backward split with a ratio of 1:4.
| Last Split Date | Dec 19, 2023 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 3.09 |
| Piotroski F-Score | 4 |